So, you wanted 3 potential PR's consolidated in one PR right before Christmas? Makes no sense. Everyone knows launching a product in biotech/Pharma around the holidays is not ideal. In this scenario, I think it is fine because of the market AMBS is entering first - RUO, not consumer. There does not need to be a media blitz days before Christmas. If you are a shareholder you should not want this. The best impact will be right after Christmas into New Years+. The data coming will likely be univariate. Then they will likely publish multivariate and align CLIA launch with the publication and a media blitz. It's happening folks. It's just a delicate roll out around the holidays with low volume and less people paying attention. Again, it's happening. Whoever, doesn't get that yet just needs to sell and move on. So naive to think that Pharma is not salivating for this product. It saves them millions and will be way more accurate. Contracts will be coming. Remember the 50+ meetings Gerald mentioned from BIO a while back? I am sure that happens at every conference - I wonder if they discuss Lympro. I wonder if ICON knows any Pharma companies that want a new blood based diagnostic for their Alzheimer's clinical trial. I bet they know all of them.